240 related articles for article (PubMed ID: 27214767)
1. Comparing a tapering strategy to the standard dosing regimen of TNF inhibitors in rheumatoid arthritis patients with low disease activity.
Plasencia C; Wolbink G; Krieckaert CL; Kneepkens EL; Turk S; Jurado T; Martínez-Feito A; Navarro-Compán V; Bonilla G; Villalba A; Peiteado D; Nuño L; Martín-Mola E; Nurmohamed MT; van der Kleij D; Rispens T; Pascual-Salcedo D; Balsa A
Clin Exp Rheumatol; 2016; 34(4):655-62. PubMed ID: 27214767
[TBL] [Abstract][Full Text] [Related]
2. Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity.
Plasencia C; Kneepkens EL; Wolbink G; Krieckaert CL; Turk S; Navarro-Compán V; L'Ami M; Nurmohamed MT; van der Horst-Bruinsma I; Jurado T; Diego C; Bonilla G; Villalba A; Peiteado D; Nuño L; van der Kleij D; Rispens T; Martín-Mola E; Balsa A; Pascual-Salcedo D
J Rheumatol; 2015 Sep; 42(9):1638-46. PubMed ID: 26178279
[TBL] [Abstract][Full Text] [Related]
3. A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes.
Bouman CAM; van der Maas A; van Herwaarden N; Sasso EH; van den Hoogen FHJ; den Broeder AA
Rheumatology (Oxford); 2017 Jun; 56(6):973-980. PubMed ID: 28339738
[TBL] [Abstract][Full Text] [Related]
4. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
[TBL] [Abstract][Full Text] [Related]
5. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?
Ibrahim F; Lorente-Cánovas B; Doré CJ; Bosworth A; Ma MH; Galloway JB; Cope AP; Pande I; Walker D; Scott DL
Rheumatology (Oxford); 2017 Nov; 56(11):2004-2014. PubMed ID: 28968858
[TBL] [Abstract][Full Text] [Related]
6. Impact of Stopping Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis Patients' Burden of Disease.
Ghiti Moghadam M; Ten Klooster PM; Vonkeman HE; Kneepkens EL; Klaasen R; Stolk JN; Tchetverikov I; Vreugdenhil SA; van Woerkom JM; Goekoop-Ruiterman YPM; Landewé RBM; van Riel PLCM; van de Laar MAFJ; Jansen TL;
Arthritis Care Res (Hoboken); 2018 Apr; 70(4):516-524. PubMed ID: 28692770
[TBL] [Abstract][Full Text] [Related]
7. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial.
van Herwaarden N; van der Maas A; Minten MJ; van den Hoogen FH; Kievit W; van Vollenhoven RF; Bijlsma JW; van den Bemt BJ; den Broeder AA
BMJ; 2015 Apr; 350():h1389. PubMed ID: 25858265
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial.
Bouman CA; van Herwaarden N; van den Hoogen FH; Fransen J; van Vollenhoven RF; Bijlsma JW; Maas AV; den Broeder AA
Ann Rheum Dis; 2017 Oct; 76(10):1716-1722. PubMed ID: 28606961
[TBL] [Abstract][Full Text] [Related]
9. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study).
Fautrel B; Pham T; Alfaiate T; Gandjbakhch F; Foltz V; Morel J; Dernis E; Gaudin P; Brocq O; Solau-Gervais E; Berthelot JM; Balblanc JC; Mariette X; Tubach F
Ann Rheum Dis; 2016 Jan; 75(1):59-67. PubMed ID: 26103979
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial.
Vanier A; Mariette X; Tubach F; Fautrel B;
Value Health; 2017 Apr; 20(4):577-585. PubMed ID: 28407999
[TBL] [Abstract][Full Text] [Related]
11. Does combined clinical and ultrasound assessment allow selection of individuals with rheumatoid arthritis for sustained reduction of anti-tumor necrosis factor therapy?
Marks JL; Holroyd CR; Dimitrov BD; Armstrong RD; Calogeras A; Cooper C; Davidson BK; Dennison EM; Harvey NC; Edwards CJ
Arthritis Care Res (Hoboken); 2015 May; 67(6):746-53. PubMed ID: 25605045
[TBL] [Abstract][Full Text] [Related]
12. Drug outcome survey to evaluate anti-TNF treatment in rheumatoid arthritis: an Italian observational study (the DOSE study).
Anecchino C; Fanizza C; Marino V; Romero M;
Clin Exp Rheumatol; 2015; 33(6):779-87. PubMed ID: 26575614
[TBL] [Abstract][Full Text] [Related]
13. The BeSt way of withdrawing biologic agents.
Allaart CF; Lems WF; Huizinga TW
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S14-8. PubMed ID: 24129130
[TBL] [Abstract][Full Text] [Related]
14. Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.
Einarsson JT; Geborek P; Saxne T; Kapetanovic MC
J Rheumatol; 2015 May; 42(5):741-8. PubMed ID: 25684762
[TBL] [Abstract][Full Text] [Related]
15. Tapering and discontinuation of TNF-α blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission.
Alivernini S; Peluso G; Fedele AL; Tolusso B; Gremese E; Ferraccioli G
Arthritis Res Ther; 2016 Feb; 18():39. PubMed ID: 26842890
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis.
Sung YK; Cho SK; Kim D; Choi CB; Won S; Bang SY; Cha HS; Choe JY; Chung WT; Hong SJ; Jun JB; Kim HA; Kim J; Kim SK; Kim TH; Lee HS; Lee J; Lee J; Lee SS; Lee SW; Lee YA; Nah SS; Suh CH; Yoo DH; Yoon BY; Bae SC;
Rheumatol Int; 2017 Jun; 37(6):975-982. PubMed ID: 28132102
[TBL] [Abstract][Full Text] [Related]
17. Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial.
Ghiti Moghadam M; Vonkeman HE; Ten Klooster PM; Tekstra J; van Schaardenburg D; Starmans-Kool M; Brouwer E; Bos R; Lems WF; Colin EM; Allaart CF; Meek IL; Landewé R; Bernelot Moens HJ; van Riel PL; van de Laar MA; Jansen TL;
Arthritis Rheumatol; 2016 Aug; 68(8):1810-7. PubMed ID: 26866428
[TBL] [Abstract][Full Text] [Related]
18. Limited value for ultrasonography in predicting flare in rheumatoid arthritis patients with low disease activity stopping TNF inhibitors.
Lamers-Karnebeek FB; Luime JJ; Ten Cate DF; Teerenstra S; Swen NWAA; Gerards AH; Hendrikx J; van Rooyen EM; Voorneman R; Haagsma C; Basoski N; de Jager M; Ghiti Moghadam M; Efde MN; Goekoop-Ruiterman YPM; van Riel PLCM; Jacobs JWG; Jansen TL
Rheumatology (Oxford); 2017 Sep; 56(9):1560-1565. PubMed ID: 28595367
[TBL] [Abstract][Full Text] [Related]
19. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
van den Bemt BJ; den Broeder AA; Snijders GF; Hekster YA; van Riel PL; Benraad B; Wolbink GJ; van den Hoogen FH
Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
[TBL] [Abstract][Full Text] [Related]
20. Patient-perceived flares in rheumatoid arthritis: A sub-analysis of the STRASS treatment tapering strategy trial.
Portier A; Gossec L; Tubach F; Alfaiate T; Pham T; Saraux A; Soubrier M; Schaeverbeke T; Maillefert JF; Mariette X; Hajage D; Fautrel B
Joint Bone Spine; 2017 Oct; 84(5):577-581. PubMed ID: 27932278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]